Moreover, additional research is required to ascertain whether the adjunctive use of SGLT2 inhibitors provides significant benefits for kidney outcomes beyond the concern of an increased risk of ketoacidosis in individuals with T1D. This evidence concerns the gene SLC5A2 and type 1 diabetes mellitus.